REFERENCES
1. Graña X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995;11:211-9.
2. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-31.
3. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-66.
5. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009;11:R77.
6. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016;375:1738-48.
7. Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 2017;35:3638-46.
8. Crespo I, Vital AL, Gonzalez-Tablas M, Patino MdC, Otero A, et al. Molecular and genomic alterations in glioblastoma multiforme. Am J Pathol 2015;185:1820-33.
9. Hayashi T, Adachi K, Ohba S, Hirose Y. The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells. J Neurooncol 2013;115:169-78.
10. Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs 2013;22:723-38.
11. Taylor JW, Parikh M, Phillips JJ, James CD, Molinaro AM, et al. Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. J Neurooncol 2018;140:477-83.
12. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol 1993;3:255-68.
13. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
14. Karcher S, Steiner HH, Ahmadi R, Zoubaa S, Vasvari G, et al. Different angiogenic phenotypes in primary and secondary glioblastomas. Int J Cancer 2006;118:2182-9.
15. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1999;1:44-51.
16. Li R, Li H, Yan W, Yang P, Bao Z, et al. Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution. Oncotarget 2015;6:7318-24.
17. Korshunov A, Sycheva R, Golanov A. Genetically distinct and clinically relevant subtypes of glioblastoma defined by array-based comparative genomic hybridization (array-CGH). Acta Neuropathol 2006;111:465-74.
18. Morokoff A, Ng W, Gogos A, Kaye AH. Molecular subtypes, stem cells and heterogeneity: implications for personalised therapy in glioma. J Clin Neurosci 2015;22:1219-26.
19. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res 2013;19:764-72.
20. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
21. Cooper LA, Gutman DA, Long Q, Johnson BA, Cholleti SR, et al. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One 2010;5:e12548.
22. Ducray F, Idbaih A, de Reynies A, Bieche I, Thillet J, et al. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer 2008;7:41.
23. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014;343:189-93.
24. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73.
25. Network CGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
26. Wang Q, Hu B, Hu X, Kim H, Squatrito M, et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell 2017;32:42-56.e6.
27. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
28. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
29. Quiros S, Roos WP, Kaina B. Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles. Cell Cycle 2010;9:168-78.
30. Murphy AC, Weyhenmeyer B, Schmid J, Kilbride SM, Rehm M, et al. Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: a systems medicine approach. Cell Death Dis 2013;4:e629.
31. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006;24:2563-9.
32. Cai X, Sughrue ME. Glioblastoma: new therapeutic strategies to address cellular and genomic complexity. Oncotarget 2018;9:9540-54.
33. Upadhyay RK. Drug delivery systems, CNS protection, and the blood brain barrier. Biomed Res Int 2014;2014:869269.
34. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006;25:4798-811.
35. Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 2007;48:403-7.
36. Ruano Y, Mollejo M, Camacho FI, Rodriguez de Lope A, Fiano C, et al. Identification of survival-related genes of the phosphatidylinositol 3’-kinase signaling pathway in glioblastoma multiforme. Cancer 2008;112:1575-84.
37. Strik H, Deininger M, Streffer J, Grote E, Wickboldt J, et al. BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry 1999;67:763-8.
38. Fulda S. Molecular pathways: targeting inhibitor of apoptosis proteins in cancer--from molecular mechanism to therapeutic application. Clin Cancer Res 2014;20:289-95.
39. Hsieh P, Yamane K. DNA mismatch repair: molecular mechanism, cancer, and ageing. Mech Ageing Dev 2008;129:391-407.
40. Russell P, Nurse P. cdc25+ functions as an inducer in the mitotic control of fission yeast. Cell 1986;45:145-53.
41. Draetta G, Brizuela L, Potashkin J, Beach D. Identification of p34 and p13, human homologs of the cell cycle regulators of fission yeast encoded by cdc2+ and suc1+. Cell 1987;50:319-25.
44. Chen YJ, Dominguez-Brauer C, Wang Z, Asara JM, Costa RH, et al. A conserved phosphorylation site within the forkhead domain of FoxM1B is required for its activation by cyclin-CDK1. J Biol Chem 2009;284:30695-707.
45. Marais A, Ji Z, Child ES, Krause E, Mann DJ, et al. Cell cycle-dependent regulation of the forkhead transcription factor FOXK2 by CDK.cyclin complexes. J Biol Chem 2010;285:35728-39.
46. Tomashevski A, Webster DR, Grammas P, Gorospe M, Kruman II. Cyclin-C-dependent cell-cycle entry is required for activation of non-homologous end joining DNA repair in postmitotic neurons. Cell Death Differ 2010;17:1189-98.
47. Aggarwal P, Vaites LP, Kim JK, Mellert H, Gurung B, et al. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell 2010;18:329-40.
48. Dickinson LA, Edgar AJ, Ehley J, Gottesfeld JM. Cyclin L is an RS domain protein involved in pre-mRNA splicing. J Biol Chem 2002;277:25465-73.
49. Loyer P, Trembley JH, Grenet JA, Busson A, Corlu A, et al. Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection. J Biol Chem 2008;283:7721-32.
50. Lam PY, Di Tomaso E, Ng HK, Pang JC, Roussel MF, et al. Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme. Br J Neurosurg 2000;14:28-32.
51. Ye X, Zhu C, Harper JW. A premature-termination mutation in the Mus musculus cyclin-dependent kinase 3 gene. Proc Natl Acad Sci U S A 2001;98:1682-6.
52. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999;402:615-22.
53. Shupp A, Casimiro MC, Pestell RG. Biological functions of CDK5 and potential CDK5 targeted clinical treatments. Oncotarget 2017;8:17373-82.
54. Hagmann H, Taniguchi Y, Pippin JW, Kauerz HM, Benzing T, et al. Cyclin I and p35 determine the subcellular distribution of Cdk5. Am J Physiol Cell Physiol 2015;308:C339-47.
55. Harper JW, Elledge SJ. The role of Cdk7 in CAK function, a retro-retrospective. Genes Dev 1998;12:285-9.
56. Serizawa H, Makela TP, Conaway JW, Conaway RC, Weinberg RA, et al. Association of Cdk-activating kinase subunits with transcription factor TFIIH. Nature 1995;374:280-2.
57. Shiekhattar R, Mermelstein F, Fisher RP, Drapkin R, Dynlacht B, et al. Cdk-activating kinase complex is a component of human transcription factor TFIIH. Nature 1995;374:283-7.
58. Hengartner CJ, Myer VE, Liao SM, Wilson CJ, Koh SS, et al. Temporal regulation of RNA polymerase II by Srb10 and Kin28 cyclin-dependent kinases. Mol Cell 1998;2:43-53.
59. Rickert P, Corden JL, Lees E. Cyclin C/CDK8 and cyclin H/CDK7/p36 are biochemically distinct CTD kinases. Oncogene 1999;18:1093.
60. Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 1997;13:261-91.
61. Kasten M, Giordano A. Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity. Oncogene 2001;20:1832-8.
62. Yu DS, Zhao R, Hsu EL, Cayer J, Ye F, et al. Cyclin-dependent kinase 9-cyclin K functions in the replication stress response. EMBO Rep 2010;11:876-82.
63. Bagella L, Giacinti C, Simone C, Giordano A. Identification of murine cdk10: association with Ets2 transcription factor and effects on the cell cycle. J Cell Biochem 2006;99:978-85.
64. Boyer MJ, Cheng T. The CDK inhibitors: potential targets for therapeutic stem cell manipulations? Gene Therapy 2008;15:117-25.
66. Marques-Torrejon MA, Porlan E, Banito A, Gomez-Ibarlucea E, Lopez-Contreras AJ, et al. Cyclin-dependent kinase inhibitor p21 controls adult neural stem cell expansion by regulating Sox2 gene expression. Cell Stem Cell 2013;12:88-100.
67. Pippa R, Espinosa L, Gundem G, Garcia-Escudero R, Dominguez A, et al. p27Kip1 represses transcription by direct interaction with p130/E2F4 at the promoters of target genes. Oncogene 2012;31:4207-20.
68. Li H, Collado M, Villasante A, Matheu A, Lynch CJ, et al. p27(Kip1) directly represses Sox2 during embryonic stem cell differentiation. Cell Stem Cell 2012;11:845-52.
69. Akiyama T, Ohuchi T, Sumida S, Matsumoto K, Toyoshima K. Phosphorylation of the retinoblastoma protein by cdk2. Proc Natl Acad Sci U S A 1992;89:7900-4.
70. Chung J, Cho JW, Baek WK, Suh SI, Kwon TK, et al. Expression of RB C pocket fragments in HSF induces delayed cell cycle progression and sensitizes to apoptosis upon cellular stresses. Cell Prolif 2002;35:247-56.
71. Wu CL, Zukerberg LR, Ngwu C, Harlow E, Lees JA. In vivo association of E2F and DP family proteins. Mol Cell Biol 1995;15:2536-46.
72. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002;89:213-28.
73. Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, et al. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci U S A 1999;96:1002-7.
74. Zhu X, Ohtsubo M, Bohmer RM, Roberts JM, Assoian RK. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J Cell Biol 1996;133:391-403.
75. Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development 2013;140:3079-93.
76. Bregman DB, Pestell RG, Kidd VJ. Cell cycle regulation and RNA polymerase II. Front Biosci 2000;5:D244-57.
77. Nemet J, Jelicic B, Rubelj I, Sopta M. The two faces of Cdk8, a positive/negative regulator of transcription. Biochimie 2014;97:22-7.
78. Garriga J, Grana X. Cellular control of gene expression by T-type cyclin/CDK9 complexes. Gene 2004;337:15-23.
79. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015;14:130-46.
80. Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 2011;104:1862-8.
81. Murphy C, Dickler M. The role of CDK4/6 inhibition in breast cancer. Oncologist 2015;20:483-490.
82. Finn R, Martin M, Rugo H, Jones S, Im SA, et al. PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). J Clin Oncol 2016;34:507.
83. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016;17:425-39.
84. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 2018;36:2465-72.
85. Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 2018;19:904-15.
86. Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs 2014;32:825-37.
87. Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017;35:2875-84.
88. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996;56:2973-8.
89. Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 1994;201:589-95.
90. Caracciolo V, Laurenti G, Romano G, Carnevale V, Cimini AM, et al. Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development. Cell Cycle 2012;11:1202-16.
91. Cobanoglu G, Turacli I, Ozkan A, Ekmekci A. Flavopiridol’s antiproliferative effects in glioblastoma multiforme. J Cancer Res Ther 2016;12:811-7.
92. Alonso M, Tamasdan C, Miller DC, Newcomb EW. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Mol Cancer Ther 2003;2:139-50.
93. Newcomb EW, Tamasdan C, Entzminger Y, Arena E, Schnee T, et al. Flavopiridol inhibits the growth of GL261 gliomas in vivo: implications for malignant glioma therapy. Cell Cycle 2004;3:230-4.
94. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997;243:527-36.
95. Leitch AE, Lucas CD, Marwick JA, Duffin R, Haslett C, et al. Cyclin-dependent kinases 7 and 9 specifically regulate neutrophil transcription and their inhibition drives apoptosis to promote resolution of inflammation. Cell Death Differ 2012;19:1950-61.
96. Kolodziej M, Goetz C, Di Fazio P, Montalbano R, Ocker M, et al. Roscovitine has anti-proliferative and pro-apoptotic effects on glioblastoma cell lines: A pilot study. Oncol Rep 2015;34:1549-56.
97. Kim EH, Kim SU, Shin DY, Choi KS. Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 2004;23:446-56.
98. Murphy AC, Weyhenmeyer B, Noonan J, Kilbride SM, Schimansky S, et al. Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis. Apoptosis 2014;19:629-42.
99. Pandey V, Ranjan N, Narne P, Babu PP. Roscovitine effectively enhances antitumor activity of temozolomide in vitro and in vivo mediated by increased autophagy and Caspase-3 dependent apoptosis. Sci Rep 2019;9:5012.
100. Menn B, Bach S, Blevins TL, Campbell M, Meijer L, et al. Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models. PLoS One 2010;5:e12117.
101. Brasca MG, Amboldi N, Ballinari D, Cameron A, Casale E, et al. Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem 2009;52:5152-63.
102. Albanese C, Alzani R, Amboldi N, Degrassi A, Festuccia C, et al. Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier. Br J Pharmacol 2013;169:156-66.
103. Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010;9:2344-53.
104. Nguyen TK, Grant S. Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism. Mol Cancer Ther 2014;13:662-74.
105. Chen Z, Wang Z, Pang JC, Yu Y, Bieerkehazhi S, et al. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity. Sci Rep 2016;6:29090.
106. Jane EP, Premkumar DR, Cavaleri JM, Sutera PA, Rajasekar T, et al. Dinaciclib, a cyclin-dependent kinase inhibitor promotes proteasomal degradation of Mcl-1 and enhances ABT-737-mediated cell death in malignant human glioma cell lines. J Pharmacol Exp Ther 2016;356:354-65.
107. Law ME, Corsino PE, Narayan S, Law BK. Cyclin-dependent kinase inhibitors as anticancer therapeutics. Mol Pharmacol 2015;88:846-52.
108. Ali MA, Choy H, Habib AA, Saha D. SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia 2007;9:370-81.
109. Ali MA, Reis A, Ding LH, Story MD, Habib AA, et al. SNS-032 prevents hypoxia-mediated glioblastoma cell invasion by inhibiting hypoxia inducible factor-1alpha expression. Int J Oncol 2009;34:1051-60.
110. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 2009;113:4637-45.
111. Conroy A, Stockett DE, Walker D, Arkin MR, Hoch U, et al. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol 2009;64:723-32.
112. Erbayraktar Z, Alural B, Erbayraktar RS, Erkan EP. Cell division cycle 7-kinase inhibitor PHA-767491 hydrochloride suppresses glioblastoma growth and invasiveness. Cancer Cell Int 2016;16:88.
113. Newcomb EW, Tamasdan C, Entzminger Y, Alonso J, Friedlander D, et al. Flavopiridol induces mitochondrial-mediated apoptosis in murine glioma GL261 cells via release of cytochrome c and apoptosis inducing factor. Cell Cycle 2003;2:243-50.
114. Michaud K, Solomon DA, Oermann E, Kim JS, Zhong WZ, et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 2010;70:3228-38.
115. Whittaker S, Madani D, Joshi S, Chung SA, Johns T, et al. Combination of palbociclib and radiotherapy for glioblastoma. Cell Death Discov 2017;3:17033.
116. Sepulveda-Sanchez JM, Gil MJG, Alonso M, Salgado MÁV, Vicente E, et al. Phase II trial of palbociclib in recurrent RB-positive anaplastic oligodendroglioma: a Spanish group for research in neurooncology (GEINO) trial. J Clin Oncol 2019;37:2038.
117. Patel YT, Davis A, Baker SJ, Campagne O, Stewart CF. CNS penetration of the CDK4/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors. Cancer Chemother Pharmacol 2019;84:447-52.
118. Martinez-Chavez A, van Hoppe S, Rosing H, Lebre MC, Tibben M, et al. P-glycoprotein limits ribociclib brain exposure and CYP3A4 restricts its oral bioavailability. Mol Pharm 2019;16:3842-52.
119. Tien AC, Bao X, Derogatis A, Kim S, Mehta S, et al. ACTR-45. Phase 0/2 study of ribociclib in patients with recurrent glioblastoma. Neuro-Oncology 2018;20:vi21.
120. Raub TJ, Wishart GN, Kulanthaivel P, Staton BA, Ajamie RT, et al. Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft. Drug Metab Dispos 2015;43:1360-71.
121. Tolaney SM, Lin NU, Thornton D, Klise S, Costigan TM, et al. Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer. J Clin Oncol 2017;35:1019.
122. Tsang J, Sung S, Gosa L, Meetze K, Cloughesy T, et al. EXTH-67. TG02, a brain-penetrant multi-CDK inhibitor, potently suppresses MYC-driven glioblastoma. Neuro Oncol 2017;19:vi87-8.
123. Su YT, Chen R, Wang H, Song H, Zhang Q, et al. Novel targeting of transcription and metabolism in glioblastoma. Clin Cancer Res 2018;24:1124-37.
124. Le Rhun E, von Achenbach C, Lohmann B, Silginer M, Schneider H, et al. Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition. Int J Cancer 2019;145:242-53.
